Robert Malenka Sells 21,262 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 21,262 shares of the stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $18.55, for a total transaction of $394,410.10. Following the transaction, the director owned 371,885 shares of the company’s stock, valued at approximately $6,898,466.75. This represents a 5.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Maplight Therapeutics Trading Down 4.8%

NASDAQ:MPLT opened at $17.69 on Friday. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $21.55. The firm has a market capitalization of $802.60 million and a P/E ratio of -0.48. The firm has a 50-day moving average of $17.62.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Ratings Changes

MPLT has been the subject of a number of recent analyst reports. Leerink Partners started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price objective for the company. Weiss Ratings initiated coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective on the stock. Morgan Stanley began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 price objective for the company. Finally, Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.